Everything below concerns GLP-1 receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
That is, the change in the internal energy of the substance within a volume is the negative of the amount carried out of the volume by the flow of material across the boundary plus the work done compressing the material on the boundary minus the flow of heat out through the boundary. More generally, it is possible to incorporate source terms.
When Burger King Corporation began franchising in 1959, it used a regional model where franchisees purchased the right to open stores within a geographic region. These franchise agreements granted BKC very little oversight control of its franchisees and resulted in issues of product quality control, store image and design, and operational procedures. During the 1970s, structural deficiencies in Burger King's franchise system became increasingly problematic for Pillsbury. A major example was the relationship between Burger King and Louisiana-based franchisee Chart House, Burger King's largest franchisee group at the time with over 350 locations in the United States. The company's owners, William and James Trotter, made several moves to take over or acquire Burger King during the 1970s, all of which were spurned by Pillsbury. After the failed attempts to acquire the company, the relationship between Chart House and Burger King soured and eventually devolved into a lawsuit. Chart House eventually spun off its Burger King operations in the early 1980s into a holding company called DiversiFoods which, in turn, was acquired by Pillsbury in 1984 and absorbed into Burger King's operations. As part of the franchising reorganization segment of Operation Phoenix, Donald N. Smith initiated a restructuring of future franchising agreements in 1978.
=== Sidearms === Enfield No. 2 – In service early on in the Cold War. Webley Revolver – Substitute for Enfield No 2. Browning Hi-Power – Main sidearm during the Cold War. Walther PP - .32 ACP model issued to fast jet pilots, .22LR caliber model issued to the Ulster Defence Regiment as a personal protection weapon. SIG Sauer P226 - Special forces issue in the late 1980s Walther P5 - P5 Compact issued to the Royal Irish Regiment (Home Service) and Ulster Defence Regiment as a personal protection weapon in the 1980s, with a small number also being issued to special forces.
Sources: en.wikipedia.org
The Congress of Vienna instituted a territorial adjustment between Hanover and Prussia to form more contiguous borders. Hanover increased its area substantially, gaining the Prince-Bishopric of Hildesheim, East Frisia, the Prince-Bishopric of Osnabrück, the Lower County of Lingen and the northern part of the Prince-Bishopric of Münster. Hanover also annexed territories that had previously been ruled in personal union by its Elector, such as the Duchies of Bremen-Verden and the County of Bentheim. It lost those parts of Saxe-Lauenburg to the northeast of the Elbe, which was assigned in personal union to Denmark, except the Amt Neuhaus. Further small exclaves in the east were lost. Hanover comprised a number of territories, which had been Imperial Estates within the Holy Roman Empire. Their respective governments, now called provincial governments, were organised according to partially very old traditions, including different levels of estate participation in rule. In 1823, the kingdom was reorganised into high-bailiwicks (German: Landdrosteien, singular: Landdrostei), each led by a high-bailiff (German: Landdrost) according to unitary standards, doing away with the inherited provincial peculiarities. The high-bailiwicks were subdivided into bailiwicks (German: Ämter, singular Amt), presided by a bailiff (Amtmann, plural Amtleute). The high-bailiwicks, named after their capitals, were the following:
== Precautions == Sulfuryl chloride is toxic, corrosive, and acts as a lachrymator. It releases hydrogen chloride upon contact with water, as well as donor solvents such as dimethyl sulfoxide and dimethylformamide.
This elevation leads to increased brain-derived neurotrophic factor (BDNF) levels, which in turn enhance dendritic branching and spine density in neurons of the nucleus accumbens and prefrontal cortex, potentially persisting for weeks after drug cessation. In transgenic mice engineered to express ΔFosB in the nucleus accumbens and dorsal striatum, heightened behavioral sensitization to cocaine has been observed. These mice self-administer cocaine at lower doses and display a greater propensity for relapse after withdrawal ΔFosB also enhances sensitivity to reward by upregulating the AMPA receptor subunit GluR2 and downregulating the expression of dynorphin. Cocaine use has also been shown to increase DNA damage in the brains of rodents. During subsequent DNA repair, enduring alterations in chromatin structure may arise, such as DNA methylation and methylation or acetylation of histones at the repair loci. These modifications may result in lasting epigenetic "scars", which are believed to contribute to the persistent epigenetic changes observed in cocaine addiction.
Sources: en.wikipedia.org
The sickness was aggravated by the intense heat and the appalling effluvium arising from the 90 Siberian sledge-dogs we had on deck. These dogs were procured from the Samoyedes in the North of Siberia and were the first dogs ever introduced in Antarctic exploration. On the return trip, the dogs were left on Native Island, New Zealand. Due to quarantine requirements, many of the dogs were killed but a few remained. Nine of the remaining dogs were bought by Ernest Shackleton. Robert Falcon Scott brought twenty Samoyeds with him during his 1902 journey. The dogs struggled under the conditions Scott placed them in, with four dogs pulling heavily loaded sleds through 45 cm (18 in) of snow with bleeding feet. Scott blamed their failure on rotten dried fish.
Natural nitrogen (7N) consists of two stable isotopes: the vast majority (99.62%) of naturally occurring nitrogen is nitrogen-14, with the remainder (0.38%) being nitrogen-15. Thirteen radioisotopes are also known, with atomic masses ranging from 9 to 23, along with three nuclear isomers. All of these radioisotopes are short-lived, the longest-lived being 13N with a half-life of 9.965 minutes. All of the others have half-lives shorter than ten seconds. Isotopes lighter than the stable ones generally decay to isotopes of carbon, and those heavier beta decay to isotopes of oxygen. Nitrogen-13 is a positron emitter and one of the main isotopes used in medical PET scans.
== External links == "Interferon beta-1a". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on July 21, 2020. "Interferon Beta-1a Intramuscular Injection". MedlinePlus.
=== The no common mechanism (NCM) model and maximum parsimony === In 1997, Tuffley and Steel described a model that they named the no common mechanism (NCM) model. The topology of the maximum likelihood tree for a specific dataset given the NCM model is identical to the topology of the optimal tree for the same data given the maximum parsimony criterion. The NCM model assumes all of the data (e.g., homologous nucleotides, amino acids, or morphological characters) are related by a common phylogenetic tree. Then
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.